Séhédic et al. constructed [188Re]Re-loaded lipid nanocapsules (LNCs) modified with 12G5 antibodies to target C-X-C chemokine receptor type 4 (CXCR4), a receptor involved in GBM tumour growth and invasiveness mediated by matrix metalloproteinases (MMPs) (Zhang et al. 2005). The gene discussed is CXCR4; the disease is glioblastoma.